Oliver Peters

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7452875/publications.pdf

Version: 2024-02-01

		57758	29157
161	12,695	44	104
papers	citations	h-index	g-index

183	183	183	17099
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
2	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
3	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
4	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
5	An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nature Neuroscience, 2012, 15, 827-835.	14.8	647
6	Identification and Characterization of Circular RNAs As a New Class of Putative Biomarkers in Human Blood. PLoS ONE, 2015, 10, e0141214.	2.5	542
7	Cerebral amyloid-Î² PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurology, The, 2011, 10, 424-435.	10.2	491
8	Inhibition of IL-12/IL-23 signaling reduces Alzheimer's diseaseâ€“like pathology and cognitive decline. Nature Medicine, 2012, 18, 1812-1819.	30.7	359
9	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	2.5	347
10	Prevalence and prognosis of Alzheimerâ€™s disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284
11	Increased Formation of Reactive Oxygen Species after Permanent and Reversible Middle Cerebral Artery Occlusion in the Rat. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 196-205.	4.3	274
12	Amyloid Î² peptide ratio 42/40 but not AÎ²42 correlates with phosphoâ€Tau in patients with lowâ€and highâ€CSF AÎ²40 load. Journal of Neurochemistry, 2007, 101, 1053-1059.	3.9	237
13	Different Mechanisms Promote Astrocyte Ca²⁺Waves and Spreading Depression in the Mouse Neocortex. Journal of Neuroscience, 2003, 23, 9888-9896.	3.6	183
14	Cortical Spreading Depression Induces Proinflammatory Cytokine Gene Expression in the Rat Brain. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 218-225.	4.3	161
15	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Molecular Systems Biology, 2020, 16, e9356.	7.2	157
16	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
17	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
18	Activity-dependent ATP-waves in the Mouse Neocortex are Independent from Astrocytic Calcium Waves. Cerebral Cortex, 2006, 16, 237-246.	2.9	131

#	Article	IF	Citations
19	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimerâ€™s disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15.	6.2	131
20	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. Neurobiology of Aging, 2015, 36, 601-607.	3.1	125
21	Distinct expression of the neurotoxic microRNA family let-7 in the cerebrospinal fluid of patients with Alzheimer's disease. PLoS ONE, 2018, 13, e0200602.	2.5	115
22	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
23	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiology of Aging, 2008, 29, 812-818.	3.1	94
24	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 27, 404-417.	1.5	90
25	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85
26	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	7.6	83
27	Antidepressants act on glial cells: SSRIs and serotonin elicit astrocyte calcium signaling in the mouse prefrontal cortex. Journal of Psychiatric Research, 2011, 45, 242-248.	3.1	82
28	Increased Extracellular K ⁺ Concentration Reduces the Efficacy of N -methyl-<scp>d</scp> -aspartate Receptor Antagonists to Block Spreading Depression-Like Depolarizations and Spreading Ischemia. Stroke, 2005, 36, 1270-1277.	2.0	76
29	Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 58, 939-950.	2.6	74
30	Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimer's Research and Therapy, 2019, 11, 66.	6.2	74
31	A combined miRNAâ€“piRNA signature to detect Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 250.	4.8	74
32	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. Neurology, 2021, 96, .	1.1	72
33	Astrocyte Function is Modified by Alzheimer's Disease-like Pathology in Aged Mice. Journal of Alzheimer's Disease, 2009, 18, 177-189.	2.6	71
34	Human endogenous retrovirus HERV-K(HML-2) RNA causes neurodegeneration through Toll-like receptors. JCI Insight, 2020, 5, .	5.0	68
35	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
36	Cognitive subtypes of probable Alzheimer's disease robustly identified inÂfour cohorts. Alzheimer's and Dementia, 2017, 13, 1226-1236.	0.8	59

#	Article	IF	Citations
37	PLD3 in non-familial Alzheimer's disease. Nature, 2015, 520, E3-E5.	27.8	58
38	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimerâ€™s dementia. Alzheimer's Research and Therapy, 2017, 9, 84.	6.2	58
39	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
40	Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, e1134-e1143.	1.1	58
41	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
42	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 537-547.	10.2	55
43	Genome-Wide Association Study of Vascular Dementia. Stroke, 2012, 43, 315-319.	2.0	51
44	Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15097-15102.	7.1	50
45	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. Alzheimer's and Dementia, 2016, 12, 872-881.	0.8	50
46	Association of SORL1 gene variants with Alzheimer's disease. Brain Research, 2009, 1264, 1-6.	2.2	49
47	A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. Journal of Nutrition, Health and Aging, 2012, 16, 544-548.	3.3	48
48	Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S269-76.	0.8	47
49	Alzheimer Amyloid Peptide AÎ²42 Regulates Gene Expression of Transcription and Growth Factors. Journal of Alzheimer's Disease, 2015, 44, 613-624.	2.6	47
50	Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. Psychiatry Research - Neuroimaging, 2010, 182, 244-250.	1.8	46
51	SUCLG2 identified as both a determinator of CSF AÎ²1â€“42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658.	2.9	45
52	Influence of SORL1 gene variants: Association with CSF amyloid-Î² products in probable Alzheimer's disease. Neuroscience Letters, 2008, 440, 68-71.	2.1	43
53	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. PLoS ONE, 2014, 9, e100812.	2.5	41
54	Validation of the Erlangen Score Algorithm for the Prediction of the Development ofÂDementia due to Alzheimerâ€™s Disease inÂPre-Dementia Subjects. Journal of Alzheimer's Disease, 2015, 48, 433-441.	2.6	41

#	Article	IF	Citations
55	Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. Neurology, 2015, 84, 1261-1268.	1.1	41
56	Methods in endogenous steroid profiling â€“ A comparison of gas chromatography mass spectrometry (GCâ€“MS) with supercritical fluid chromatography tandem mass spectrometry (SFC-MS/MS). Journal of Chromatography A, 2018, 1554, 101-116.	3.7	41
57	The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology, 2014, 83, 1353-1358.	1.1	40
58	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	7.7	40
59	Temperature and nitric oxide control spontaneous calcium transients in astrocytes. Cell Calcium, 2008, 43, 285-295.	2.4	37
60	Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimerâ€™s disease based on multicenter diffusion tensor imaging. Journal of Neurology, 2019, 266, 2465-2474.	3.6	35
61	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.8	35
62	Zinc ions are endogenous modulators of neurotransmitterâ€stimulated capacitative Ca²⁺ entry in both cultured and in situ mouse astrocytes. European Journal of Neuroscience, 2005, 21, 1626-1634.	2.6	34
63	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	3.1	34
64	Beyond surgery: clinical and economic impact of Enhanced Recovery After Surgery programs. BMC Health Services Research, 2018, 18, 1008.	2.2	33
65	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
66	Personalized risk for clinical progression in cognitively normal subjectsâ€”the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	6.2	30
67	Long-Term Stability of Alzheimer's Disease Biomarker Proteins in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2011, 26, 255-262.	2.6	29
68	A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 2021, 13, e13659.	6.9	29
69	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's diseaseâ€”Data from three memory clinic studies. Alzheimer's and Dementia, 2019, 15, 185-193.	0.8	28
70	Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment. Current Alzheimer Research, 2011, 8, 893-901.	1.4	27
71	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	3.1	27
72	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	3.1	27

#	Article	IF	Citations
73	Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. Scientific Reports, 2017, 7, 9529.	3.3	27
74	User experience and clinical effectiveness with two wearable global positioning system devices in home dementia care. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 636-644.	3.7	27
75	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimerâ€™s disease. Neuron, 2022, 110, 1009-1022.e4.	8.1	27
76	The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. Psychiatry Research - Neuroimaging, 2010, 183, 44-51.	1.8	26
77	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	2.4	26
78	A Possible New Diagnostic Biomarker in Early Diagnosis of Alzheimers Disease. Current Alzheimer Research, 2009, 6, 519-524.	1.4	25
79	Combined treatment with memantine and galantamineâ€CR comparedÂwith galantamineâ€CR only in antidementia drug naÃ¯ve patients with mildâ€toâ€moderate Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2015, 1, 198-204.	3.7	25
80	Technology for home dementia care: A prototype locating system put to the test. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 332-338.	3.7	25
81	Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimer's and Dementia, 2023, 19, 487-497.	0.8	25
82	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.8	24
83	The Latent Dementia Phenotype Î´ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 49, 547-560.	2.6	23
84	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimerâ€™s disease. PLoS ONE, 2019, 14, e0218111.	2.5	23
85	Prevalence of abnormal Alzheimerâ€™s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimer's Research and Therapy, 2019, 11, 8.	6.2	23
86	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.8	22
87	Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 191.	6.2	21
88	Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimerâ€™s Disease: A Pilot Study. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 277-289.	1.3	20
89	Plasma Amyloid Concentration in Alzheimerâ€™s Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimerâ€™s Disease Cases from Controls. Journal of Alzheimer's Disease, 2020, 74, 1285-1294.	2.6	20
90	Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 801-813.	2.6	19

#	Article	IF	Citations
91	Configuration in smart service systems: A practiceâ€based inquiry. Information Systems Journal, 2019, 29, 1256-1292.	6.9	19
92	Measurement of ERK 1/2 in CSF from Patients with Neuropsychiatric Disorders and Evidence for the Presence of the Activated Form. Journal of Alzheimer's Disease, 2009, 18, 613-622.	2.6	18
93	Bupropion for the Treatment of Apathy in Alzheimer Disease. JAMA Network Open, 2020, 3, e206027.	5.9	18
94	Apolipoprotein E4 disrupts the neuroprotective action of sortilin in neuronal lipid metabolism and endocannabinoid signaling. Alzheimer's and Dementia, 2020, 16, 1248-1258.	0.8	18
95	Impaired Synaptic Plasticity in the Surround of Perinatally Aquired Dysplasia in Rat Cerebral Cortex. Cerebral Cortex, 2004, 14, 1081-1087.	2.9	17
96	A Polymorphic Microsatellite Repeat within the ECE-1c Promoter Is Involved in Transcriptional Start Site Determination, Human Evolution, and Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 16807-16820.	3.6	17
97	Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 610-618.	2.4	17
98	Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkersâ€"results from the DELCODE study. Alzheimer's Research and Therapy, 2020, 12, 131.	6.2	17
99	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimerâ€™s disease spectrum. NeuroImage: Clinical, 2020, 28, 102495.	2.7	17
100	Amyloid pathology but notAPOEÎµ4 status is permissive for tau-related hippocampal dysfunction. Brain, 2022, 145, 1473-1485.	7.6	17
101	Prediction of Alzheimerâ€™s Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status. Journal of Alzheimer's Disease, 2017, 61, 373-388.	2.6	15
102	Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimerâ€™s disease spectrum. NeuroImage: Clinical, 2021, 29, 102533.	2.7	15
103	Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 626974.	3.4	15
104	Prominent Non-Memory Deficits in Alzheimerâ€™s Disease Are Associated with Faster Disease Progression. Journal of Alzheimer's Disease, 2018, 65, 1029-1039.	2.6	14
105	Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status. Journal of Alzheimer's Disease, 2021, 79, 493-509.	2.6	14
106	Donâ€™t forget about tau: the effects of ApoE4 genotype on Alzheimerâ€™s disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairmentâ€"data from the Dementia Competence Network. Journal of Neural Transmission, 2022, 129, 477-486.	2.8	14
107	APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 37, 389-401.	2.6	13
108	Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimerâ€™s disease: a voxel-based lesion mapping study. Alzheimer's Research and Therapy, 2015, 7, 27.	6.2	13

#	Article	IF	Citations
109	Exploring Genetic Associations of Alzheimerâ€™s Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. Frontiers in Aging Neuroscience, 2018, 10, 340.	3.4	12
110	Resting-State Network Alterations Differ between Alzheimerâ€™s Disease Atrophy Subtypes. Cerebral Cortex, 2021, 31, 4901-4915.	2.9	12
111	Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimerâ€™s Disease Spectrum. Journal of Alzheimer's Disease, 2022, 85, 1267-1282.	2.6	12
112	Correlation of florbetaben PET imaging and the amyloid peptide AÃŸ42 in cerebrospinal fluid. Psychiatry Research - Neuroimaging, 2017, 265, 98-101.	1.8	11
113	Golgin A4 in CSF and granulovacuolar degenerations of patients with Alzheimer disease. Neurology, 2018, 91, e1799-e1808.	1.1	11
114	Cognitive behavioural therapy for the treatment of late life depression: study protocol of a multicentre, randomized, observer-blinded, controlled trial (CBTlate). BMC Psychiatry, 2019, 19, 423.	2.6	11
115	Overcoming barriers to the adoption of locating technologies in dementia care: a multi-stakeholder focus group study. BMC Geriatrics, 2021, 21, 378.	2.7	11
116	Association of N-Acetylaspartate and Cerebrospinal Fluid AÎ²42 in Dementia. Journal of Alzheimer's Disease, 2011, 27, 393-399.	2.6	10
117	Combination of Structural MRI andÂFDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients. Journal of Alzheimer's Disease, 2016, 54, 1319-1331.	2.6	9
118	Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 441-446.	2.6	9
119	Atrophy outcomes in multicentre clinical trials on Alzheimer's disease: Effect of different processing and analysis approaches on sample sizes. World Journal of Biological Psychiatry, 2011, 12, 109-113.	2.6	8
120	P3â€591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1352.	0.8	8
121	Computerâ€assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 726-736.	2.4	8
122	Value of a Panel of 6 Serum Biomarkers to Differentiate Between Healthy Controls and Mild Cognitive Impairment Due to Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2020, 34, 318-324.	1.3	7
123	Pursuing Experimental Reproducibility: An Efficient Protocol for the Preparation of Cerebrospinal Fluid Samples for NMR-Based Metabolomics and Analysis of Sample Degradation. Metabolites, 2020, 10, 251.	2.9	6
124	No association of the variant rs11887120 in DNMT3A with cognitive decline in individuals with mild cognitive impairment. Epigenomics, 2016, 8, 593-598.	2.1	5
125	CORRELATION OF CSF- AND MRI-BIOMARKERS AND PROGRESSION OF COGNITIVE DECLINE IN AN OPEN LABEL MCI TRIAL. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-5.	2.7	5
126	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 87, 545-555.	2.6	5

#	Article	IF	Citations
127	A rare heterozygous TREM2 coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2. Human Mutation, 2020, 41, 169-181.	2.5	4
128	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12223.	2.4	4
129	A Comparison of Operational Definitions for Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, 88, 1663-1678.	2.6	4
130	Association of a CAMK2A genetic variant with logical memory performance and hippocampal volume in the elderly. Brain Research Bulletin, 2020, 161, 13-20.	3.0	3
131	Concomitants of Depressive Symptoms in Memory Clinic Patients. GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry, 2021, 34, 37-44.	0.5	3
132	Association Between Ginkgo Biloba Extract Prescriptions and Dementia Incidence in Outpatients with Mild Cognitive Impairment in Germany: A Retrospective Cohort Study. Journal of Alzheimer's Disease, 2022, , 1-7.	2.6	3
133	[P3â€“437]: LATENTâ€FACTOR STRUCTURE OF THE DELCODE STUDY NEUROPSYCHOLOGICAL TEST BATTERY. Alzheimer's and Dementia, 2017, 13, P1136.	0.8	2
134	[P1â€“122]: WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER's DISEASE, AND NEURAL NETWORKS. Alzheimer's and Dementia, 2017, 13, P287.	0.8	2
135	[TDâ€Pâ€018]: A LONGITUDINAL USER STUDY TESTING TWO LOCATING SYSTEMS IN HOME DEMENTIA CARE. Alzheimer's and Dementia, 2017, 13, P165.	0.8	2
136	[P2â€“390]: LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER's DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT. Alzheimer's and Dementia, 2017, 13, P779.	0.8	1
137	[P3â€“218]: TAU PLASMA LEVELS IN SUBJECTIVE COGNITIVE DECLINE: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P1021.	0.8	1
138	Value of Neuropsychological Tests to Identify Patients with Depressive Symptoms on the Alzheimerâ€™s Disease Continuum. Journal of Alzheimer's Disease, 2020, 78, 819-826.	2.6	1
139	Decreased cortical thickness in individuals with subjective cognitive decline with and without CSFâ€ADâ€pathology: Data from the DELCODE Study. Alzheimer's and Dementia, 2020, 16, e044741.	0.8	1
140	Presenilin 1 Gene Mutation (M139V) in a German Family with Early-Onset Alzheimerâ€™s Disease: A Case Report. Archives of Clinical Neuropsychology, 2021, , .	0.5	1
141	Memorability analysis for diagnostic photographs in cognitive assessment: Linking behavioral performance with biomarker status. Alzheimer's and Dementia, 2021, 17, .	0.8	1
142	P4-174: Evaluation of Cutoff Values For Fully Automated Hippocampus Volumetry With Fsl-First For Prediction Of Alzheimer's Disease Dementia In Mci Subjects. , 2016, 12, P1084-P1085.		0
143	[P4â€“139]: APPLICATION OF THE â€˜A/T/Nâ€™ BIOMARKER CLASSIFICATION SYSTEM IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: CONVERSION RATES TO AD AND OTHER DEMENTIAS. Alzheimer's and Dementia, 2017, 13, P1310.	0.8	0
144	[P4â€“532]: OBJECT AND SCENE MEMORY ARE DIFFERENTIALLY ASSOCIATED WITH CSF MARKERS OF ALZHEIMER's DISEASE AND MRI VOLUMETRY. Alzheimer's and Dementia, 2017, 13, P1553.	0.8	0

#	Article	IF	Citations
145	P1â€379: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P443.	0.8	0
146	P3â€327: NEUROPSYCHIATRIC SYMPTOMS IN ATâ€RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1206.	0.8	0
147	P2â€455: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P894.	0.8	0
148	P4â€142: HOW RELATIONSHIP DYNAMICS BETWEEN PERSONS WITH DEMENTIA AND CAREGIVERS REGARDING SUBJECTIVE TECHNOLOGICAL AFFINITY WITH LOCATING SYSTEMS PLAY OUT OVER TIME. Alzheimer's and Dementia, 2018, 14, P1493.	0.8	0
149	P3â€366: MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES OF ALZHEIMER'S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1228.	0.8	0
150	ICâ€Pâ€155: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P131.	0.8	0
151	P1â€140: A GENERIC LATENT VARIABLE APPROACH FOR MEASURING COGNITIVE RESERVE: PHENOTYPE VALIDATION AND GENETIC ASSOCIATION RESULTS. Alzheimer's and Dementia, 2018, 14, P328.	0.8	0
152	THE APOE-Îµ4 ALLELE AND AGE SYNERGISTICALLY DRIVE DISEASE PROGRESSION IN ALZHEIMERâ€™S DISEASE. Innovation in Aging, 2019, 3, S943-S943.	0.1	0
153	ICâ€Pâ€122: ALTERATIONS OF INTRINSIC CONNECTIVITY IN POSTERIOR DEFAULT MODE NETWORK ACROSS AT RISK STAGES OF ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2019, 15, P101.	0.8	0
154	ICâ€Pâ€028: PATTERNS OF INCREASED AND DECREASED PRECUNEUS FUNCTIONAL CONNECTIVITY IN SCD DEPENDING ON AMYLOID STATUS. Alzheimer's and Dementia, 2019, 15, P35.	0.8	0
155	ICâ€Pâ€016: CORTICAL AMYLOID BURDEN CORRELATES WITH ATROPHY OF THE POSTERIOR PART OF THE NUCLEUS BASALIS MEYNERT IN AMYLOIDâ€POSITIVE SCD. Alzheimer's and Dementia, 2019, 15, P25.	0.8	0
156	Identification of a Cascade of Changes in Activities of Daily Living Preceding Short-Term Clinical Deterioration in Mild Alzheimerâ€™s Disease Dementia via Lead-Lag Analysis. Journal of Alzheimer's Disease, 2020, 76, 1005-1015.	2.6	0
157	Association between SCDâ€Plus features and GDS factors in subjective cognitive decline and healthy controls in the studies DELCODE and SILCODE. Alzheimer's and Dementia, 2021, 17, .	0.8	0
158	Cost of illness of apathy in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
159	Characterization of the NIAâ€AA Research Framework stage 2 in the longitudinal multicenter DELCODE study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
160	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
161	Prediction of amyloidâ€positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize numberâ€neededâ€toâ€screen. Alzheimer's and Dementia, 2021, 17, .	0.8	0